FENNEC PHARMACEUTICALS INC.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-9.7M | $-436.0K | $-16.0M | $-23.7M | $-17.3M | $-18.1M | $-12.8M | $-9.9M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $7.0M | $5.1M | $5.4M | $4.1M | $3.7M | $2.8M | $2.7M | $1.8M |
| Net Cash from Operating Activities | $-12.5M | $27.0M | $-17.1M | $-18.1M | $-14.2M | $-15.6M | $-9.1M | $-7.8M |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | — | — | — | — | — | — |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | — | — | — | — | — | — | — | $0 |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $22.6M | $-13.6M | $6.6M | $20.7M | $5.0M | $32.3M | $-71.0K | $2.3M |
| Net Change in Cash | $10.2M | $13.4M | $-10.5M | $2.7M | $-9.2M | $16.7M | $-9.1M | $-5.5M |
| Free Cash Flow | — | — | — | — | — | — | — | — |